Stay updated with breaking news from Reduction Oxidation Potential. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Relief Therapeutics Holding SA / Key word(s): Study22-Sep-2022 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Relief Therapeutics Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epid...
Relief Therapeutics Holding SA / Key word(s): Study Relief Therapeutics Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa at Ann & Robert H. Lurie Children's Hospital of Chicago 22-Sep-2022 / 07:00 CET/CEST Release of an ad hoc anno...
Relief Therapeutics Holding SA / Key word(s): Study Relief Therapeutics Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa at Ann & Robert
EQS Group-Ad-hoc: RELIEF THERAPEUTICS Holding AG / Key word(s): Scientific publication Relief Therapeutics Reports Two Publications of Positive Data on Nexodyn(R) AOS for Hard-to-Heal Ulcers 20-Oct-2021
EQS Group-Ad-hoc: RELIEF THERAPEUTICS Holding AG / Key word(s): Scientific publication Relief's Subsidiary, APR Applied Pharma Research, Reports Data Published in Journal of Wound Care, Indicating